Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Americans for Safe Access

APRIL 2, 2019

The Americans for Safe Access 2019 Unity Conference, themed The Price of Being a Medical Cannabis Patient, featured over a hundred patients from all over America visiting their representatives in Congress and the Senate to promote the Medical Cannabis Control Act of 2019. Which agency will have authority over medical cannabis policy?

Access 100

Access DEA Policy Patients 100

United Patients Group

JANUARY 15, 2023

However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. The DEA definition of a Schedule 1 substance is : Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Book a consultation today.

THC 117

THC CBD DEA Cannabinoids 117

NORML

JANUARY 17, 2019

As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. Click here to send a message to your federal lawmaker and urge them to support the measure. .

Clinical Trials 223

Clinical Trials Legislation DEA Strains 223

FloridaMarijuana.net

JULY 8, 2018

PTSD patients lack the necessary endocannabinoids to fill the receptor sites properly. Medical marijuana and cannabinoids can be used to treat a patient’s physical and psychological health, alleviating the debilitating symptoms of PTSD. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs).

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

The Blunt Truth

APRIL 2, 2020

DEA GUIDANCE. Scientists at the Scottsdale Research Institute have filed suit against the agency, claiming that the DEA has changed its interpretation of federal statutes and treaty obligations, without detailing how it arrived at its new view of the law. So now Idaho stands alone as the only state where no form of cannabis is legal.

DEA 101

DEA Hemp Packaging Recreational 101

Veriheal

SEPTEMBER 13, 2022

With legalization, patients and consumers have more freedom in product choice, and many are turning to homegrown cannabis. The change he pointed out was in how the DEA treats marijuana seeds. Cultivation Costs for Homegrowers.

Cultivation 109

Cultivation Data DEA Dispensary 109

MedicalJane

MAY 14, 2020

It continues to enforce restrictive policies and regulations on research into the health benefits or harms of cannabis products that are available to consumers across the nation. Because of this, some cannabis companies are even investing money into facilitating their own private studies to get a better understanding of what patients need.

Sleep 95

Sleep Edibles DEA Policy 95

United Patients Group

FEBRUARY 21, 2023

On a federal level, CBD is still classified as a Schedule I drug by the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA). The post Understanding the 4 Major Differences Between CBD and THC appeared first on United Patients Group. Legality In the United States, cannabis laws are changing rapidly.

THC 52

THC CBD Patients DEA 52

Veriheal

NOVEMBER 6, 2023

Despite this massive shift in cannabis policy, however, a few states are still dragging their feet on cannabis legalization. The Act aimed to provide patients access to smokable flower for 15 medical conditions. This progressive legislation, once implemented, means a brand new slew of patients will have access to cannabis medicine.

Legalization 117

Legalization Recreational THC CBD 117

Veriheal

DECEMBER 11, 2020

Further, the DEA hasn’t exactly been helping matters, in fact, they may even be making things worse. . The DEA has thwarted research by refusing to process and approve any additional cannabis manufacturers. The agency has undergone several lawsuits filed by scientists, activists, and patients over the matter. .

DEA 71

DEA Recreational THC Dispensary 71

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Doctors and patients had to register on the Compassionate Use Registry , an online database maintained by the Florida Department of Health.

Law 126

Law Marijuana Patients Treatment 126

The Cannigma

DECEMBER 13, 2021

As a matter of fact, the Korean DEA (Drug Enforcement Agency) has been known to enter clubs and perform random drug searches. . Today, however, due to draconian government policies, the use of weed is extremely taboo. Drug pickup is available from Seoul only – no matter where in South Korea the patient resides.

Legalization 78

Legalization DEA Recreational History 78

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Nonetheless, with the increasing legalization of medical cannabis, many veterans and interest groups have asked the government to change its policies. Yes, it has.

Law 62

Law Chronic Pain Conditions Legislation 62

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

Cannabis Law Report

JANUARY 13, 2022

In The Weeds welcomes the new year, as well as a number of new cannabis laws and policies taking effect around the country in 2022. 1, Louisiana’s medical cannabis program allows patients to access smokable whole-plant flower marijuana. McGuireWoods LLP. Newsworthy Highlights. Happy 2022! Montana: As of Jan. Louisiana: As of Jan.

Dispensary 52

Dispensary Law Concentrates Patients 52

Cannabis Law Report

MARCH 3, 2022

Clinton’s drug policy record while in office has been widely criticized by advocates. He also rejected requests to lift a federal ban on harm reduction policies like syringe exchange programs.

Media 52

Media CBD Events THC 52

The Joint Blog

MARCH 4, 2021

These symptoms mainly had to do with digestion, easing nausea, vomiting, and stomach pain that patients experienced. This is partly due to the heavy involvement of the DEA throughout the production process. The biggest change to come out of the recent change was the improved negligence violation policy.

Legislation 26

Legislation CBD DEA Hemp 26

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

FEBRUARY 28, 2022

Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” 10, 2019), [link] [ [link] ]. 21 × 21. See General Information Concerning Patents , U.S.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

SEPTEMBER 20, 2019

DEA increases the cannabis research quota. The Drug Enforcement Administration (DEA) announced annual quotas for the manufacture of controlled substances for research purposes, providing for 7,000 pounds of cannabis to be used in scientific studies. The state has issued 8,000 patient and caregiver ID cards since June 28.

Vaping 40

Vaping Banking Research and Development DEA 40

CannaMD

SEPTEMBER 10, 2020

This stems from the fact that despite the ongoing legalization of both recreational and medical marijuana at the state level, cannabis is still classified as a Schedule I substance by the DEA, along with substances such as heroin, cocaine, opioids and methamphetamine.

Marijuana 59

Marijuana Therapy Data THC 59

Canna Law Blog

MAY 7, 2020

What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. POPLAR will publish original law and policy research. CR: Can you describe the existing landscape of psychedelics research?

Law 105

Law Research and Development Therapy DEA 105

SpeedWeed

MARCH 28, 2021

That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”. As a result, there has been more interest among patients, clinicians, and researchers to see if cannabis is effective in treating PTSD. . Many veterans with PTSD already use cannabis to self-treat their symptoms.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Canna Law Blog

MARCH 4, 2020

According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Veriheal

AUGUST 19, 2022

But times are changing, and leaders are now calling for revamped policies on psilocybin, hemp, and cannabis research for varying reasons. In February 2021, a lawsuit was filed against the DEA for prohibiting access for others aside from the University of Mississippi to cultivate cannabis for research purposes.

Hemp 52

Hemp DEA Access Cultivation 52

Veriheal

DECEMBER 21, 2022

The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. The law gives the U.S. attorney general 60 days to either approve a given application or request supplemental information from the marijuana research applicant.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Cannabis Law Report

MAY 24, 2022

Defendant and respondent Oakland Cannabis Buyers’ Cooperative created a medical dispensary that would serve eligible patients. The criminalization of marijuana was the result of racially motivated policies, such as the Marijuana Tax Act of 1937. The Tax Act was litigated in Leary v.

DEA 52

DEA History Medicine Marijuana 52

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. Relevant AAFP Policy. Executive Summary. Marijuana Possession for Personal Use.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

JUNE 9, 2021

If you’re moving within one of those states and are discovered to have any weed on your person, you’ll be asked to present your medical marijuana patient card. You could still find yourself dealing with Big Daddy DEA, even with a medical marijuana card at the ready, and even if you’re still within the state that issued it.

Marijuana 66

Marijuana Edibles DEA THC 66